{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Stratford-on-Avon&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.answeringMemberConstituency=Stratford-on-Avon&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Stratford-on-Avon&_metadata=all&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.answeringMemberConstituency=Stratford-on-Avon&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Stratford-on-Avon&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Stratford-on-Avon&max-questionFirstAnswered.=2021-06-07T16%3A11%3A53.97Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1328925", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1328925/answer", "answerText" : {"_value" : "

Public Health England (PHE) has published early estimates of vaccine effectiveness against symptomatic disease with the B.1.617.2 variant which are available at the following link:<\/p>

https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1<\/a><\/p>

The number of hospitalised cases and deaths from the B.1.617.2 variant of COVID-19 are currently too small to estimate vaccine effectiveness against these outcomes. PHE will continue to monitor the impact of the COVID-19 vaccines on variant B.1.617.2.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-07T15:51:17.763Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the efficacy of vaccination in preventing (a) transmission, (b) hospitalisation and (c) death arising from the B.1.617.2 variant of covid-19.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1520", "label" : {"_value" : "Biography information for Mr Mark Harper"} } , "tablingMemberConstituency" : {"_value" : "Forest of Dean"} , "tablingMemberPrinted" : [{"_value" : "Mr Mark Harper"} ], "uin" : "8562"} , {"_about" : "http://data.parliament.uk/resources/1328985", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1328985/answer", "answerText" : {"_value" : "

Children under 16 years of age, even if they are clinically extremely vulnerable (CEV), are at low risk of serious morbidity and mortality from COVID-19. There is also a lack of safety and efficacy data for COVID-19 vaccines in children. Most children under the age of 16, including those who are CEV, are therefore not recommended for routine vaccination.<\/p>

Given the very high risk of exposure to infection and outbreaks in residential settings, vaccination may be appropriate for those with severe neuro-disabilities who require frequent care in these settings. This option should be discussed between parents or guardians and the child\u2019s clinician.<\/p>

As of 1 April, due to low prevalence, shielding advice has been paused for all clinically extremely vulnerable people, including children and young people. All CEV pupils should attend their school unless they are one of the very small number of pupils under paediatric or other specialist care and have been advised by their GP or clinician not to attend. Pupils who live with someone who is CEV should continue to attend school as normal.<\/p>

More information on children and COVID-19 vaccination can be found at the following link: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984310/Greenbook_chapter_14a_7May2021.pdf<\/a><\/p>

Current guidance to individuals who are clinically extremely vulnerable, including children, can be found at the following link: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19<\/a><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-07T15:54:49.58Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of whether clinically extremely vulnerable children under 16 should be able to access covid-19 vaccines; and how many clinically extremely vulnerable children are still shielding because they do not have access to that vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4385", "label" : {"_value" : "Biography information for Dr Philippa Whitford"} } , "tablingMemberConstituency" : {"_value" : "Central Ayrshire"} , "tablingMemberPrinted" : [{"_value" : "Dr Philippa Whitford"} ], "uin" : "8628"} , {"_about" : "http://data.parliament.uk/resources/1329010", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1329010/answer", "answerText" : {"_value" : "

BEIS Ministers and officials have regular discussions with their counterparts in the Department for International Trade on a range of issues of mutual interest, including on trade and steel.<\/p>

The Trade Remedies Authority (TRA) will make a final recommendation before the UK steel safeguard measures are due to expire on 30 June 2021. My Rt. Hon. Friend the Secretary of State for International Trade may only reject a recommendation to impose a measure if she considers that it is not in the public interest or that the economic interest test has not been met. If this happens, the Secretary of State must lay down her reasons to Parliament.<\/p>

She can accept or reject a TRA recommendation as a whole but not modify or partially accept it. She cannot extend a measure if the TRA does not recommend this.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-07T16:11:53.97Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2021-05-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Iron and Steel: Safeguard Measures"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what discussions he has had with the Secretary of State for International Trade on the (a) Trade Remedies Investigations Directorate's Statement of Intended Final Determination published on 19 May 2021 and (b) impact of that statement on the economic and public interests of the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4253", "label" : {"_value" : "Biography information for Seema Malhotra"} } , "tablingMemberConstituency" : {"_value" : "Feltham and Heston"} , "tablingMemberPrinted" : [{"_value" : "Seema Malhotra"} ], "uin" : "8606"} , {"_about" : "http://data.parliament.uk/resources/1328107", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1328107/answer", "answerText" : {"_value" : "

There are currently no plans to prioritise students specifically as a group. This includes those studying abroad next academic year. Students aged 18 years old and over are prioritised on grounds of age in phase two of the COVID-19 vaccine programme if they have not been vaccinated as part of phase one. Phase two offers vaccination to all those aged 18 to 49 years old unless they fall into a higher cohort group due to age or pre-existing health condition which puts them in phase one.<\/p>

<\/p>

The Government is working closely with the devolved administrations, the higher education sector and health services across the United Kingdom to ensure that all students are able to access the vaccine efficiently and conveniently where they are eligible. The Government advises those who may be unable to receive a full course of vaccination in the UK to notify clinicians of this before they receive their vaccination. For any foreign travel, the Government advises checking GOV.UK for relevant information including information on healthcare provision.<\/p>

<\/p>

We are on track to offer a first dose of COVID-19 vaccination to all those aged 18 years old and over by 31 July.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-07T15:56:28.557Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Travel: Coronavirus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that students studying abroad in the 2021-22 academic year will have received their covid-19 vaccinations before travelling.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4786", "label" : {"_value" : "Biography information for Zarah Sultana"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Zarah Sultana"} ], "uin" : "7954"} , {"_about" : "http://data.parliament.uk/resources/1328262", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1328262/answer", "answerText" : {"_value" : "

To ensure ongoing protection for the United Kingdom\u2019s population, particularly the most vulnerable, we are preparing for a potential booster vaccination programme. Whilst we are planning for several potential scenarios, final decisions on the timing and scope of the booster programme in terms of when to give boosters to which groups and with which vaccines will not be taken until later this year, in line with results from key clinical studies. Any decision on a booster vaccination programme will be informed by independent advice from the Joint Committee for Vaccination and Immunisation (JCVI).<\/p>

As part of the National Core Studies Immunity Programme (NCSi), UK Research and Innovation (UKRI) is providing initial funding of £1.8 million for 12 months towards the OCTAVE study. The OCTAVE study will examine the effectiveness of COVID-19 vaccines in clinically at-risk groups and will help to inform planning for the booster programme. This includes COVID-19 vaccine responses in patients with certain immunosuppressed conditions, including those with inflammatory disorders, high risk cancer patient groups, blood cancer patients and patients with severe kidney and liver disease. Cancer patient groups include those with blood cancer (leukaemia, myeloma, and bone marrow (stem cell) transplants).<\/p>

Studies into the specific effect of a COVID-19 booster vaccine on certain groups have not yet been established. However, as part of the NCSi, UKRI is providing £3 million in funding towards a new research call to support projects examining one or both of the following areas - the nature and quality of COVID-19 vaccine responses, the mechanisms of immune failure that lead to either COVID-19 re-infection or vaccine breakthrough. As the nation's largest funder of health and care research, the NIHR welcomes funding applications for research into any aspect of human health, including on COVID-19 vaccination and immunocompromised individuals.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-07T15:50:36.663Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to assess the potential merits of covid-19 vaccine boosters for (a) people with blood cancer and (b) other people who are immunocompromised.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"} } , "tablingMemberConstituency" : {"_value" : "Sheffield South East"} , "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"} ], "uin" : "7732"} , {"_about" : "http://data.parliament.uk/resources/1327693", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327693/answer", "answerText" : {"_value" : "

The delivery of the vaccination programme is designed to be convenient and flexible, including in areas where there are groups with lower uptake. There is already a wide offer of vaccination settings such as religious and community centres. Local and national public health agencies are consulted on how best to utilise this flexibility to maximise uptake in groups with low vaccine uptake.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-03", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-03T16:41:08.83Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of using community development centres to help promote and administer the covid19 vaccine in areas where the take-up of the vaccine is lower than average.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "7178"} , {"_about" : "http://data.parliament.uk/resources/1327749", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327749/answer", "answerText" : {"_value" : "

To ensure ongoing protection for the United Kingdom population, particularly the most vulnerable, we are preparing for a potential booster vaccination programme. While we are planning for several potential scenarios, final decisions on the timing and scope of the booster programme will not be taken until later this year, in line with results from key clinical studies. This includes the OCTAVE study, which will examine the effectiveness of COVID-19 vaccines in clinically at-risk groups, including patients with certain immunocompromised conditions such as blood cancer.<\/p>

Any decision on a booster vaccination programme will be informed by independent advice from the Joint Committee for Vaccination and Immunisation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-02T16:21:59.603Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps is he taking to measure the value of covid-19 vaccine boosters for (a) people with blood cancer and (b) other immunocompromised groups.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4370", "label" : {"_value" : "Biography information for Jess Phillips"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Yardley"} , "tablingMemberPrinted" : [{"_value" : "Jess Phillips"} ], "uin" : "7194"} , {"_about" : "http://data.parliament.uk/resources/1327750", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327750/answer", "answerText" : {"_value" : "

As part of the COVID-19 Immunity National Core Study, UK Research and Innovation (UKRI) is providing initial funding of £1.8 million for 12 months towards the OCTAVE study, examining the effectiveness of COVID-19 vaccines in clinically at-risk groups and £3 million towards a new research call to support projects investigating COVID-19 vaccine responses and immune failure. UKRI is also supporting the COVID-19 Data and Connectivity National Core Studies Programme with an investment of up to £15.2 million, which will enable studies including the evaluation of vaccine uptake and efficacy across all populations, including people with blood cancer.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-06-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-06-02T16:26:50.537Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to provide funding for research into covid-19 vaccine efficacy among all types of blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4370", "label" : {"_value" : "Biography information for Jess Phillips"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Yardley"} , "tablingMemberPrinted" : [{"_value" : "Jess Phillips"} ], "uin" : "7195"} , {"_about" : "http://data.parliament.uk/resources/1327767", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327767/answer", "answerText" : {"_value" : "

The Government is taking a number of steps to ensure the UK is prepared to respond to current and emerging COVID-19 variants as quickly as possible. This includes:<\/p>

<\/p>